Peptide imaging agent developer Diatide of Londonderry, NH, planson issuing an initial public offering in the next several weeksthat will raise $25 million to fund ongoing product development.The firm will price its stock at $10 to $12 a share,
Peptide imaging agent developer Diatide of Londonderry, NH, plans
on issuing an initial public offering in the next several weeks
that will raise $25 million to fund ongoing product development.
The firm will price its stock at $10 to $12 a share, according
to president Richard Dean. Diatide's lead product is a technetium-99m-labeled
agent for detection of deep vein thrombosis.
Study Raises Doubt About AI Sensitivity for Smaller and Multiple Findings on Chest X-Rays
September 29th 2023In a multicenter study examining four commercially available artificial intelligence (AI) software products for chest X-rays in over 2,000 patients, researchers found sensitivity rates ranging between 33 to 61 percent for vague airspace disease and 9 to 94 percent for small pneumothorax and pleural effusion.
Seven Takeaways from New Analysis of Malpractice Cases Involving Interventional Radiologists
September 27th 2023Thirty-five percent of the interventional radiology malpractice cases involved vascular procedures and 26 percent of overall malpractice cases that went to trial resulted in plaintiff judgments with the average award being over $2 million.
2 Clarke Drive
Cranbury, NJ 08512